In the US, Golimumab (golimumab systemic) is a member of the drug class TNF alfa inhibitors and is used to treat Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis and Spondyloarthritis.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Disease-modifying antirheumatic drug, DMARD
Immunoglobulin G1, anti-(human tumor necrosis factor α) (human monoclonal CNTO 148 gamma1-chain), disulfide with human monoclonal CNTO 148 kappa-chain, dimer
- Golimumabum (Latin)
- Golimumab (German)
- Golimumab (French)
- Golimumab (Spanish)
- Golimumab (OS: USAN, BAN)
- CNTO 148 (IS: Centocor)
Centocor, Austria; Centocor, Iceland; Centocor, Latvia; Centocor, Slovenia; Centocor, United States; Centocor B.V., Lithuania; Centocor-NL, Italy; Essex, Germany; Merck Sharp & Dohme, United Kingdom; Merck Sharp & Dohme, Ireland; MSD, Switzerland; MSD, Sweden; Schering-Plough, Australia; Schering-Plough, Belgium; Schering-Plough, Canada; Schering-Plough, Spain; Schering-Plough, Finland; Schering-Plough, Croatia (Hrvatska); Schering-Plough, Norway
|BAN||British Approved Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Click for further information on drug naming conventions and International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.